Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

ALS patient Bradford Smith became the third patient to test Neuralink — and the first one to do so who had lost the ability ...

Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Reduced levels of a critical protein are linked to devastating brain diseases like Alzheimer's, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS). Surprisingly, the protein shortage ...

A former tech executive who lost her husband to amyotrophic lateral sclerosis, ALS, hopes her app will help people with the ...

Learn more about whether argenx SE or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.